Fred Tileston

@ President & CEO

Phone Number encrypt_section

Education

Stanford University

BS, MBA, Engineers Degree, Industrial Engineering; Finance and marketing; International law and finance 1965-01-01 - 1972-01-01

Work Experience

Tileston & Associates

1992-01-01 - 2010-01-01

Tileston & Associates

Skills

Strategy Team Building Business Development Project Management Teaching Marketing Strategy Research Entrepreneurship Strategic Planning Business Strategy New Business Development Public Speaking Business Planning Start-ups Mergers & Acquisitions Strategic Partnerships Nonprofits Product Development Microsoft Office Program Management

Summary

Regenerative Arthritis and Bone Medicine (RABOME) was launched in 2013 to develop and commercialize a class of drugs based on targeting mesenchymal stem cells (MSCs) to various sites of clinical relevance. Our lead molecule is RAB-001 (previously known as LLP2A-ALE) and it employs a particular receptor expressed on the surface of MSCs to target these cells to bone surfaces. The MSCs, whether endogenous or externally injected, direct new bone growth and increase existing bone mass and strength. These cells are also immune-modulating cells and they help in reducing inflammation at the directed sites. These findings have currently been demonstrated in a number of animal models for osteonecrosis, fracture healing, osteoporosis, and inflammatory arthritis. The potential opportunity for RABOME is to develop these drugs addressing a need for effective stem cell treatments in osteonecrosis, fracture healing, osteoporosis, and inflammatory arthritis (including rheumatoid arthritis).

Browse SuperAGI Directories

People Search

1 2 3 4 5 ... 22732309

Company Search

1 2 3 4 5 ... 809223

AI Native CRM for Unified Sales, Support & Marketing Accelerate growth and streamline your entire stack with AI CRM Platform